Trial reportChest2015
Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease Control.
Trial report in Chest, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.Advances in therapy · 2023Trial
- Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.American journal of respiratory and critical care medicine · 2017Trial
- Expert opinion on gray areas in asthma management: A lesson from the innovative project "revolution in asthma" of the Italian thoracic society (AIPO-ITS).Clinical and translational allergy · 2025Review
- Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4International journal of molecular sciences · 2024Article
- Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.Frontiers in immunology · 2024Article
- Genomics of Treatable Traits in Asthma.Genes · 2023Review
- Collaborative cross strain CC011/UncJ as a novel mouse model of T2-high, severe asthma.Respiratory research · 2023Article
- Transcriptomic analysis of asthma and allergic rhinitis reveals CST1 as a biomarker of unified airways.Frontiers in immunology · 2023Article
- Promising treatment biomarkers in asthma.Frontiers in drug safety and regulation · 2023Review
- Mitochondria dysfunction in airway epithelial cells is associated with type 2-low asthma.Frontiers in genetics · 2023Article
- Potentiality of impulse oscillometry to evaluate bronchodilator reversibility in untreated adult patients with newly diagnosed asthma.Journal of the Chinese Medical Association : JCMA · 2022Article
- Novel imaging phenotypes of naïve asthma patients with distinctive clinical characteristics and T2 inflammation traits.Therapeutic advances in chronic disease · 2022Article
- Worsening of asthma control after COVID-19.Frontiers in medicine · 2022Article
- Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life.Biomedicines · 2021Article
- The endogenous circadian system worsens asthma at night independent of sleep and other daily behavioral or environmental cycles.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Risk Factors Predicting Severe Asthma Exacerbations in Adult Asthmatics: A Real-World Clinical Evidence.Allergy, asthma & immunology research · 2021Article
- Review
- Article
- Area Under the Expiratory Flow-Volume Curve (AEX): Assessing Bronchodilator Responsiveness.Lung · 2020Article
- Health-Related Effects of Home Nebulization With Glycopyrronium on Difficult-to-Treat Asthma: Post-Hoc Analyses of an Observational Study.Interactive journal of medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHigh bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. This analysis compares lung function, biomarker profiles, and disease control in patients with high reversibility (HR) and low reversibility (LR) asthma.
methodsA retrospective analysis was performed with data from two completed clinical trials of similar design. Patients were divided into HR and LR subgroups based on their response to bronchodilators (HR = ΔFEV1 postbronchodilator ≥ 20%). Blood eosinophil count, serum IgE level, and fraction of exhaled nitric oxide concentration, biomarkers commonly used to stratify patients into T-helper (Th)-2-high vs Th2-low phenotypes, were measured in patients with not well controlled (1.5 ≤ Asthma Control Questionnaire [ACQ] ≤ 2.143) and very poorly controlled (ACQ > 2.143) disease.
resultsThe majority of patients in the HR and LR subgroups displayed Th2-low biomarker profiles and very poor disease control. HR was more frequently associated with Th2-high biomarker profiles (40.1% vs 29.4%, P = .006), lower lung function (FEV1, 63.5 ± 7.7% predicted vs 67.9 ± 8.4% predicted; P < .001), and atopy (93.7% vs 86.5%, P = .005).
conclusionsHR is a physiologic indicator of reduced lung function and is more often associated with elevations in Th2 biomarkers than LR in moderate to severe asthma. However, the majority of patients with HR and LR asthma in this analysis had a Th2-low biomarker profile. Moreover, a Th2-high biomarker profile was not associated with worse disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.